CRISPR-Cas9 GENE EDITING: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5074Keywords:
CRISPR-Cas9, Oncology, Infectious Diseases, Gene Editing Technologies, Personalized TherapyAbstract
The system of gene editing known as the CRISPR-Cas9 system has revolutionized the field of gene editing and provides a platform that allows for the modification of genetic sequences with precision and efficiency, having implications for both the basic research of science and for treatments. Its mechanism, which is derived from bacterial adaptive immunity, consists of a guide RNA that leads to specific epigenetic DNA sites a nuclease named Cas, to target it for cleavage; this permits gene correction, inactivation, or insertion. The clinical potential of this technology is enormous with applications ranging from hereditary diseases, oncology, and infectious diseases. Of note too, the approvals from the FDA for therapies targeted at the treatment of sickle cell anemia and beta thalassemia speaks volumes to its transformative effect on what was previously in-treatable conditions. In oncology, the technologies are increasing immunotherapies by engineering T-cells and interfering with immune checkpoints, but also working on viral genomes (e.g. HIV, HBV) and destroying antibiotic-resistance genes in bacteria. However, there are still major challenges such as off-target effects, in vivo delivery efficiency and possible immunogenicity of Cas proteins. Future advancements are dedicated to refine the use of the CRP systems using advanced variants such as base and prime editors, and to extend the toolkit by Cas12 and Cas13 for RNA/DNA targeting, as well as devising innovative delivery systems for overcoming the biological barriers. Ethical, regulatory, and societal considerations are paramount in the continued promotion and progressive growth of this technology.
References
Abdelnour, S. A., Salaka, A., Shakoori, A., Alsaffar, N., Hassanin, A. A., Abukhalil, M. H., & El‐Hack, M. E. A. (2023). Applying the CRISPR/Cas9 for treating human and animal diseases: Comprehensive review. Annals of Animal Science, 23(4), 979. https://doi.org/10.2478/aoas-2023-0009
Abhijith, K., & Thangavel, S. (2025). Advancing precision medicine: Recent innovations in gene editing technologies. Advanced Science. https://doi.org/10.1002/advs.202410237
Ahmed, M. M., Hassan, H. K., Okesanya, O. J., Ukoaka, B. M., Eshun, G., Mourid, M. R., Adigun, O. A., Ogaya, J. B., Mohamed, Z. A., & Lucero‐Prisno, D. E. (2024). CRISPR-Cas systems in the fight against antimicrobial resistance: Current status, potentials, and future directions. Infection and Drug Resistance, 5229. https://doi.org/10.2147/idr.s494327
Ahumada-Ayala, M., Aguilar-López, R., González-Stoylov, N., Palacio-Sosa, E., Cervantes‐Barragán, D. E., & Fernández‐Hernández, L. (2023). Editing the human genome with CRISPR/Cas: A review of its molecular basis, current clinical applications, and bioethical implications. Revista de Investigación Clínica, 75(1). https://doi.org/10.24875/ric.22000252
Al-Fadhli, A. H., & Jamal, W. (2024). Recent advances in gene-editing approaches for tackling antibiotic resistance threats: A review. Frontiers in Cellular and Infection Microbiology, 14, 1410115. https://doi.org/10.3389/fcimb.2024.1410115
Allemailem, K. S., Almatroudi, A., Rahmani, A. H., Alrumaihi, F., Alradhi, A. E., Al-Subaiyel, A., Algahtani, M., Almousa, R. M., Mahzari, A., Sindi, A. A. A., Dobie, G., & Khan, A. A. (2024). Recent updates of the CRISPR/Cas9 genome editing system: Novel approaches to regulate its spatiotemporal control by genetic and physicochemical strategies. International Journal of Nanomedicine, 5335. https://doi.org/10.2147/ijn.s455574
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023). Innovative strategies of reprogramming immune system cells by targeting CRISPR/Cas9-based genome-editing tools: A new era of cancer management. International Journal of Nanomedicine, 5531. https://doi.org/10.2147/ijn.s424872
Al-Ouqaili, M. T. S., Ahmad, A., Jwair, N. A., & Al‐Marzooq, F. (2025). Harnessing bacterial immunity: CRISPR-Cas system as a versatile tool in combating pathogens and revolutionizing medicine. Frontiers in Cellular and Infection Microbiology, 15, 1588446. https://doi.org/10.3389/fcimb.2025.1588446
Anliker, B., Childs, L., Rau, J., Renner, M., Schüle, S., Schuessler‐Lenz, M., & Sebe, A. (2022). Regulatory considerations for clinical trial applications with CRISPR-based medicinal products. The CRISPR Journal, 5(3), 364. https://doi.org/10.1089/crispr.2021.0148
Becerra, E., Ontiveros, V. J. S., & García‐Alcocer, G. (2022). CRISPR-Cas9-based strategies for acute lymphoblastic leukemia therapy. In IntechOpen eBooks. https://doi.org/10.5772/intechopen.106702
Bellizzi, A., Ahye, N., Jalagadugula, G., & Wollebo, H. S. (2019). A broad application of CRISPR Cas9 in infectious diseases of central nervous system. Journal of Neuroimmune Pharmacology, 14(4), 578. https://doi.org/10.1007/s11481-019-09878-7
Benz, F., Beamud, B., Laurenceau, R., Maire, A., Duportet, X., Decrulle, A., & Bikard, D. (2025). CRISPR–Cas therapies targeting bacteria. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-025-00311-8
Bharti, A., & Mudge, J. (2025). Therapeutic applications of CRISPR-Cas9 gene editing. Preprints.org. https://doi.org/10.20944/preprints202510.0771.v1
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., Dhawan, P., Akil, A. A., El‐Rifai, W., Uddin, S., Reddy, R., Singh, M., Macha, M. A., & Haris, M. (2022). Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03765-1
Bhattacharjee, R., Roy, L. D., & Choudhury, A. (2022). Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics. Discover Oncology, 13(1). https://doi.org/10.1007/s12672-022-00509-x
Bishnoi, S. (2023). CRISPR-Cas9 gene editing: Current progress and future applications. International Journal for Research in Applied Science and Engineering Technology, 11(7), 2116. https://doi.org/10.22214/ijraset.2023.55035
Biswas, I. (2025). Ethical dimensions and societal implications: Ensuring the social responsibility of CRISPR technology. Frontiers in Genome Editing, 7, 1593172. https://doi.org/10.3389/fgeed.2025.1593172
Brandes, R. P., Dueck, A., Engelhardt, S., Kaulich, M., Kupatt, C., Angelis, M. T. D., Leisegang, M. S., Noble, F. le, Moretti, A., Müller, O. J., Skryabin, B. V., Thum, T., & Wurst, W. (2021). DGK and DZHK position paper on genome editing: Basic science applications and future perspective. Basic Research in Cardiology, 116(1). https://doi.org/10.1007/s00395-020-00839-3
Butiuc-Keul, A., Farkas, A., Carpa, R., & Iordache, D. (2021). CRISPR-Cas system: The powerful modulator of accessory genomes in prokaryotes. Microbial Physiology, 32, 2. https://doi.org/10.1159/000516643
Chaudhary, M. F., Saleem, U., Khan, S., Khan, R., Asim, M., Azam, F., Sharif, M., Zainab, Z., Dilawar, A. A., & Jehanzaib, M. (2021). Cancer therapy with CRISPR/Cas9: Prospects and challenges. International Journal of Environment Agriculture and Biotechnology, 6(3), 143. https://doi.org/10.22161/ijeab.63.16
Chehelgerdi, M., Chehelgerdi, M., Khorramian‐Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy. Molecular Cancer, 23(1), 9. https://doi.org/10.1186/s12943-023-01925-5
Chen, C., Wang, Z., & Qin, Y. (2023). CRISPR/Cas9 system: Recent applications in immuno-oncology and cancer immunotherapy. Experimental Hematology and Oncology, 12(1). https://doi.org/10.1186/s40164-023-00457-4
Chen, X., Guo, R., Zhao, C., Xu, J., Song, H., Yu, H., Pilarsky, C., Nainu, F., Li, J., Zhou, X., & Zhang, J. (2022). A novel anti-cancer therapy: CRISPR/Cas9 gene editing. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.939090
Cofsky, J. C., Karandur, D., Huang, C. J., Witte, I. P., Kuriyan, J., & Doudna, J. A. (2020). CRISPR-Cas12a exploits R-loop asymmetry to form double-strand breaks. eLife, 9. https://doi.org/10.7554/elife.55143
Collias, D., & Beisel, C. L. (2021). CRISPR technologies and the search for the PAM-free nuclease. Nature Communications, 12(1). https://doi.org/10.1038/s41467-020-20633-y
Delhove, J., Osenk, I., Prichard, I., & Donnelley, M. (2019). Public acceptability of gene therapy and gene editing for human use: A systematic review. Human Gene Therapy, 31, 20. https://doi.org/10.1089/hum.2019.197
Deneault, É. (2024). Recent therapeutic gene editing applications to genetic disorders. Current Issues in Molecular Biology, 46(5), 4147. https://doi.org/10.3390/cimb46050255
Deng, H. (2024). CRISPR-Cas9 in cancer therapy: Revolutionizing oncology through targeted gene editing. E3S Web of Conferences, 553, 5046. https://doi.org/10.1051/e3sconf/202455305046
Ding, R., Long, J., Yuan, M., Jin, Y., Yang, H., Chen, M., Chen, S., & Duan, G. (2021). CRISPR/Cas system: A potential technology for the prevention and control of COVID-19 and emerging infectious diseases. Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.639108
Dubey, A. K., & Mostafavi, E. (2023). Biomaterials-mediated CRISPR/Cas9 delivery: Recent challenges and opportunities in gene therapy. Frontiers in Chemistry, 11. https://doi.org/10.3389/fchem.2023.1259435
Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023). CRISPR-Cas technology as a revolutionary genome editing tool: Mechanisms and biomedical applications. https://doi.org/10.61186/ibj.27.5.219
Eid, A., & Mahfouz, M. M. (2016). Genome editing: The road of CRISPR/Cas9 from bench to clinic. Experimental & Molecular Medicine, 48(10). https://doi.org/10.1038/emm.2016.111
Escalona‐Noguero, C., López‐Valls, M., & Sot, B. (2021). CRISPR/Cas technology as a promising weapon to combat viral infections. BioEssays, 43(4). https://doi.org/10.1002/bies.202000315
Feng, X., Li, Z. Y., Liu, Y., Chen, D., & Zhou, Z. (2024). CRISPR/Cas9 technology for advancements in cancer immunotherapy: From uncovering regulatory mechanisms to therapeutic applications. Experimental Hematology and Oncology, 13(1). https://doi.org/10.1186/s40164-024-00570-y
Foley, R. A., Sims, R. A., Duggan, E., Olmedo, J. K., Ma, R., & Jonas, S. J. (2022). Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. Frontiers in Bioengineering and Biotechnology, 10. https://doi.org/10.3389/fbioe.2022.973326
Galy, A., Berkhout, B., Breckpot, K., Pichon, C., Bloom, K., Kiem, H., Mühlebach, M. D., & McCune, J. M. (2023). Recent advances using genetic therapies against infectious diseases and for vaccination. Human Gene Therapy, 34, 896. https://doi.org/10.1089/hum.2023.123
Gleditzsch, D., Pausch, P., Müller-Esparza, H., Özcan, A., Guo, X., Bange, G., & Randau, L. (2018). PAM identification by CRISPR-Cas effector complexes: Diversified mechanisms and structures. RNA Biology, 16(4), 504. https://doi.org/10.1080/15476286.2018.1504546
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1143157
Guo, Z., Zhu, A. T., Fang, R. H., & Zhang, L. (2024). Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing. Nano Research, 17(10), 8904. https://doi.org/10.1007/s12274-024-6748-5
Hassan, Y. M., Mohamed, A., Hassan, Y., & El‐Sayed, W. M. (2025). Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. Clinical and Experimental Medicine, 25(1), 33. https://doi.org/10.1007/s10238-024-01540-8
Hawsawi, Y. M., Shams, A., Theyab, A., Siddiqui, J., Barnawee, M., Abdali, W. A., Marghalani, N. A., Alshelali, N. H., Al-Sayed, R., Alzahrani, O. R., Alqahtani, A., & Alsulaiman, A. M. (2022). The state-of-the-art of gene editing and its application to viral infections and diseases including COVID-19. Frontiers in Cellular and Infection Microbiology, 12. https://doi.org/10.3389/fcimb.2022.869889
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020). Gene editing and CRISPR in the clinic: Current and future perspectives. Bioscience Reports, 40(4). https://doi.org/10.1042/bsr20200127
Huang, C., Li, Q., & Li, J. (2022). Site-specific genome editing in treatment of inherited diseases: Possibility, progress, and perspectives. Medical Review, 2(5), 471. https://doi.org/10.1515/mr-2022-0029
Ikhtiar, F., Jamal, A., & Bokhari, S. M. (2025). Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies. Discover Oncology, 16(1). https://doi.org/10.1007/s12672-025-03535-7
Jachowski, A., Marcinkowski, M., Szydłowski, J., Grabarczyk, O., Nogaj, Z., Marcin, L. P., Pławski, A., Jagodzińśki, P. P., & Słowikowski, B. (2023). Modern therapies of nonsmall cell lung cancer. Journal of Applied Genetics, 64(4), 695. https://doi.org/10.1007/s13353-023-00786-4
Janik, E., Niemcewicz, M., Ceremuga, M., Krzowski, Ł., Saluk, J., & Bijak, M. (2020). Various aspects of a gene editing system—CRISPR–Cas9. International Journal of Molecular Sciences, 21(24), 9604. https://doi.org/10.3390/ijms21249604
Javaid, D., Ganie, S. Y., Hajam, Y. A., & Reshi, M. S. (2022). CRISPR/Cas9 system: A reliable and facile genome editing tool in modern biology. Molecular Biology Reports, 49(12), 12133. https://doi.org/10.1007/s11033-022-07880-6
Jungfer, K., Moravčík, Š., Garcia‐Doval, C., Knörlein, A., Hall, J., & Jínek, M. (2025). Mechanistic determinants and dynamics of cA6 synthesis in type III CRISPR-Cas effector complexes. Nucleic Acids Research, 53(2). https://doi.org/10.1093/nar/gkae1277
Kanbar, K., Darzi, R. E., & Jaalouk, D. E. (2024). Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed. Frontiers in Genetics, 15. https://doi.org/10.3389/fgene.2024.1434002
Karimi, M. A., Paryan, M., Fard, G. B., Sadeghian, H., Zarrinfar, H., & Bafghi, M. H. (2025). Challenges and opportunities in the application of CRISPR-Cas9: A review on genomic editing and therapeutic potentials. https://doi.org/10.1159/000547334
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022). CRISPR in cancer biology and therapy. Nature Reviews Cancer, 22(5), 259. https://doi.org/10.1038/s41568-022-00441-w
Khan, S., Mahmood, M. S., Rahman, S. U., Zafar, H., Habibullah, S., Khan, Z., & Ahmad, A. (2018). CRISPR/Cas9: The Jedi against the dark empire of diseases. Journal of Biomedical Science, 25(1). https://doi.org/10.1186/s12929-018-0425-5
Khlidj, Y. (2023). What did CRISPR-Cas9 accomplish in its first 10 years? Biochemia Medica, 33(3), 283. https://doi.org/10.11613/bm.2023.030601
Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023). Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine. Genes & Diseases, 11(1), 268. https://doi.org/10.1016/j.gendis.2023.02.027
Kimchi, O., Larsen, B. B., Dunkley, O. R. S., Velthuis, A. J. W. te, & Myhrvold, C. (2023). RNA structure modulates Cas13 activity and enables mismatch detection. bioRxiv. https://doi.org/10.1101/2023.10.05.560533
Koonin, E. V., Gootenberg, J. S., & Abudayyeh, O. O. (2023). Discovery of diverse CRISPR-Cas systems and expansion of the genome engineering toolbox. Biochemistry, 62(24), 3465. https://doi.org/10.1021/acs.biochem.3c00159
Kumari, S., Singh, S. K., Sharma, V., Kumar, R., Mathur, M., Upadhyay, T. K., & Prajapat, R. K. (2021). CRISPR-Cas: A continuously evolving technology. The Indian Journal of Agricultural Sciences, 91(9). https://doi.org/10.56093/ijas.v91i9.116069
Kuo, H., Prupes, J., Chou, C., & Finkelstein, I. J. (2024). Massively parallel profiling of RNA-targeting CRISPR-Cas13d. Nature Communications, 15(1), 498. https://doi.org/10.1038/s41467-024-44738-w
Lee, H., & Sashital, D. G. (2022). Creating memories: Molecular mechanisms of CRISPR adaptation. Trends in Biochemical Sciences, 47(6), 464. https://doi.org/10.1016/j.tibs.2022.02.004
Leonard, A., & Tisdale, J. F. (2024). A new frontier: FDA approvals for gene therapy in sickle cell disease. Molecular Therapy, 32(2), 264. https://doi.org/10.1016/j.ymthe.2024.01.015
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024). Harnessing the evolving CRISPR/Cas9 for precision oncology. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05570-4
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023). CRISPR/Cas9 therapeutics: Progress and prospects. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01309-7
Lin, H., Li, G., Peng, X., Deng, A., Ye, L., Shi, L., Wang, T., & He, J. (2021). The use of CRISPR/Cas9 as a tool to study human infectious viruses. Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.590989
Lin, J., Feng, M., Zhang, H., & She, Q. (2020). Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase. Cell Discovery, 6(1), 29. https://doi.org/10.1038/s41421-020-0160-4
Liu, T. Y., & Doudna, J. A. (2020). Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation. Journal of Biological Chemistry, 295(42), 14473. https://doi.org/10.1074/jbc.rev120.007034
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine, 4(3), 179. https://doi.org/10.1093/pcmedi/pbab014
Liu, X., Gao, M., & Bao, J. (2025). Precisely targeted nanoparticles for CRISPR-Cas9 delivery in clinical applications. https://doi.org/10.3390/nano15070540
Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., Li, L., Li, J., & Han, X. (2023). Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Molecular Cancer, 22(1). https://doi.org/10.1186/s12943-023-01738-6
Losito, M., Smith, Q. M., Newton, M. D., Cuomo, M. E., & Rueda, D. (2021). Cas12a target search and cleavage on force-stretched DNA. Physical Chemistry Chemical Physics, 23(47), 26640. https://doi.org/10.1039/d1cp03408a
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023). Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery, 22(11), 875. https://doi.org/10.1038/s41573-023-00762-x
Makarova, K. S., Shmakov, S., Wolf, Y. I., Mutz, P., Altae-Tran, H., Beisel, C. L., Brouns, S. J. J., Charpentier, E., Cheng, D. R., Doudna, J. A., Haft, D. H., Horvath, P., Moineau, S., Mojica, F. J. M., Pausch, P., Pinilla‐Redondo, R., Shah, S. A., Šikšnys, V., Terns, M. P., … Koonin, E. V. (2025). An updated evolutionary classification of CRISPR–Cas systems including rare variants. Nature Microbiology, 10(12), 3346. https://doi.org/10.1038/s41564-025-02180-8
McGrail, M., Sakuma, T., & Bleris, L. (2022). Genome editing. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-24850-x
Mengstie, M. A., & Wondimu, B. Z. (2021). Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics, 353. https://doi.org/10.2147/btt.s326422
Moon, S. B., Kim, D. Y., Ko, J.-H., & Kim, Y.-S. (2019). Recent advances in the CRISPR genome editing tool set. Experimental & Molecular Medicine, 51(11), 1. https://doi.org/10.1038/s12276-019-0339-7
Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023). An update on the application of CRISPR technology in clinical practice. Molecular Biotechnology, 66(2), 179. https://doi.org/10.1007/s12033-023-00724-z
Naqvi, M. M., Lee, L., Montaguth, O. E. T., Diffin, F. M., & Szczelkun, M. D. (2022). CRISPR–Cas12a-mediated DNA clamping triggers target-strand cleavage. Nature Chemical Biology, 18(9), 1014. https://doi.org/10.1038/s41589-022-01082-8
Natanzi, A. S., Poudineh, M., Karimi, E., Khaledi, A., & Kashani, H. H. (2025). Innovative approaches to combat antibiotic resistance: Integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections. BMC Medicine, 23(1). https://doi.org/10.1186/s12916-025-04323-4
Navarro, C., Díaz, M. P., Durán, P., Castro, A. V., Díaz, A., Cano, C., Carbonell, A., Solano-Jimenez, D.-S., Rivera-Porras, D., Contreras-Velásquez, J., & Bermúdez, V. (2025). CRISPR-Cas systems: A functional perspective and innovations. International Journal of Molecular Sciences, 26(8), 3645. https://doi.org/10.3390/ijms26083645
Nelson, J. P., Tomblin, D., Barbera, A., & Smallwood, M. (2023). The divide so wide: Public perspectives on the role of human genome editing in the US healthcare system. Public Understanding of Science, 33(2), 189. https://doi.org/10.1177/09636625231189955
Nussenzweig, P. M., & Marraffini, L. A. (2020). Molecular mechanisms of CRISPR-Cas immunity in bacteria. Annual Review of Genetics, 54(1), 93. https://doi.org/10.1146/annurev-genet-022120-112523
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021). CRISPR/Cas9 gene-editing in cancer immunotherapy: Promoting the present revolution in cancer therapy and exploring more. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.674467
Pacesa, M., Pelea, O., & Jínek, M. (2024). Past, present, and future of CRISPR genome editing technologies. Cell, 187(5), 1076. https://doi.org/10.1016/j.cell.2024.01.042
Palacios, A. M., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024). Revolutionizing in vivo therapy with CRISPR/Cas genome editing: Breakthroughs, opportunities and challenges. Frontiers in Genome Editing, 6. https://doi.org/10.3389/fgeed.2024.1342193
Pandey, V., Sharma, S., & Pokharel, Y. R. (2025). Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology. Molecular Therapy — Nucleic Acids, 36(4), 102717. https://doi.org/10.1016/j.omtn.2025.102717
Paraan, M., Nasef, M., Chou-Zheng, L., Khweis, S. A., Schoeffler, A. J., Hatoum-Aslan, A., Stagg, S. M., & Dunkle, J. A. (2023). The structure of a Type III-A CRISPR-Cas effector complex reveals conserved and idiosyncratic contacts to target RNA and crRNA among Type III-A systems. PLoS ONE, 18(6). https://doi.org/10.1371/journal.pone.0287461
Park, H., Yu, S., & Koo, T. (2025). Gene editing in cancer therapy: Overcoming drug resistance and enhancing precision medicine. Cancer Gene Therapy, 32(12), 1293. https://doi.org/10.1038/s41417-025-00959-9
Park, S.-J., Lee, G. J., Cho, S. M., & Choi, E.-H. (2025). Recent applications, future perspectives, and limitations of the CRISPR-Cas system. Molecular Therapy — Nucleic Acids, 36(3), 102634. https://doi.org/10.1016/j.omtn.2025.102634
Parums, D. V. (2024). Editorial: First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent β-thalassemia. Medical Science Monitor, 30. https://doi.org/10.12659/msm.944204
Qian, Y., Zhou, D., Li, M., Zhao, Y., Liu, H., Li, Y., Ying, Z., & Huang, G. (2023). Application of CRISPR-Cas system in the diagnosis and therapy of ESKAPE infections. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1223696
Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022). Current advances of CRISPR-Cas technology in cell therapy. Cell Insight, 1(6), 100067. https://doi.org/10.1016/j.cellin.2022.100067
Rahmat, Z. S., Ali, M. H., Talha, M., & Hasibuzzaman, M. A. (2024). FDA approval of Casgevy and Lyfgenia: A dual breakthrough in gene therapies for sickle cell disease. Annals of Medicine and Surgery, 86(9), 4966. https://doi.org/10.1097/ms9.0000000000002409
Ramasamy, J., Jaisankar, D., Ramamoorthy, S., Jothibasu, D., & Ravikumar, N. (2025). Targeted drug delivery through CRISPR–Cas9: Bridging biopharmaceutics and pharmacokinetics. International Journal of Applied Pharmaceutics, 17(5). https://doi.org/10.22159/ijap.2025v17i5.54502
Rostami, N., Gomari, M. M., Choupani, E., Abkhiz, S., Fadaie, M., Eslami, S. S., Mahmoudi, Z., Zhang, Y., Puri, M., Monfared, F. N., Demireva, E. Y., Uversky, V. N., Smith, B. R., & Bencherif, S. A. (2024). Exploring advanced CRISPR delivery technologies for therapeutic genome editing. Small Science, 4(10), 2400192. https://doi.org/10.1002/smsc.202400192
Schmietow, B., Eberbach, W., & Kaulich, M. (2019). Gene editing in der Krebsforschung: Technische, ethische und rechtliche Aspekte. Der Onkologe, 25, 116. https://doi.org/10.1007/s00761-019-0599-9
Schuijff, M., de Jong, M. D. T., & Dijkstra, A. M. (2021). A Q methodology study on divergent perspectives on CRISPR-Cas9 in the Netherlands. BMC Medical Ethics, 22(1). https://doi.org/10.1186/s12910-021-00615-5
Sharma, A., & Giri, A. K. (2024). Engineering CRISPR/Cas9 therapeutics for cancer precision medicine. Frontiers in Genetics, 15, 1309175. https://doi.org/10.3389/fgene.2024.1309175
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020). CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases. Molecular Therapy, 29(2), 571. https://doi.org/10.1016/j.ymthe.2020.09.028
Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023). Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing. https://doi.org/10.1007/s13346-023-01320-z
Stella, G., & Marraffini, L. A. (2023). Type III CRISPR-Cas: Beyond the Cas10 effector complex. Trends in Biochemical Sciences, 49(1), 28. https://doi.org/10.1016/j.tibs.2023.10.006
Tagarro, C. de la F., Martín-González, D., Lucas, A. D., Bordel, S., & Santos‐Beneit, F. (2024). Current knowledge on CRISPR strategies against antimicrobial-resistant bacteria. Antibiotics, 13(12), 1141. https://doi.org/10.3390/antibiotics13121141
Taylor, D. W., Schwartz, E. A., Bravo, J. P. K., Ahsan, M., Macias, L. A., McCafferty, C. L., Dangerfield, T. L., Walker, J. N., Brodbelt, J. S., Palermo, G., Fineran, P. C., & Fagerlund, R. D. (2023). Type III CRISPR-Cas effectors act as protein-assisted ribozymes during RNA cleavage. Research Square. https://doi.org/10.21203/rs.3.rs-2837968/v1
Vajen, B., Ronez, J., Rathje, W., Heinisch, L., Ebeling, S., Gebhard, U., Hößle, C., & Schlegelberger, B. (2021). Students’ attitudes towards somatic genome editing versus genome editing of the germline using an example of familial leukemia. Journal of Community Genetics, 12(3), 397. https://doi.org/10.1007/s12687-021-00528-1
Villiger, L., Joung, J., Koblan, L. W., Weissman, J. S., Abudayyeh, O. O., & Gootenberg, J. S. (2024). CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology, 25(6), 464. https://doi.org/10.1038/s41580-023-00697-6
Wang, J. Y., Pausch, P., & Doudna, J. A. (2022). Structural biology of CRISPR–Cas immunity and genome editing enzymes. Nature Reviews Microbiology, 20(11), 641. https://doi.org/10.1038/s41579-022-00739-4
Wang, M. (2020). CRISPR/Cas9: Magic scissors for genome editing. Chinese Science Bulletin, 65(36), 4168. https://doi.org/10.1360/tb-2020-1514
Wang, S. W., Gao, C., Zheng, Y. M., Yi, L., Lu, J., Huang, X. Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022). Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Molecular Cancer, 21(1), 57. https://doi.org/10.1186/s12943-022-01518-8
Wu, Y., Battalapalli, D., Hakeem, M. J., Selamneni, V., Zhang, P., Draz, M. S., & Ruan, Z. (2021). Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. Journal of Nanobiotechnology, 19(1). https://doi.org/10.1186/s12951-021-01132-8
Wu, Y., & Zhang, H. (2023). Treatment of infectious diseases by in vivo gene editing. National Science Open. https://doi.org/10.1360/nso/20220061
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024). Breaking genetic shackles: The advance of base editing in genetic disorder treatment. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1364135
Xu, Y., Le, H., Wu, Q., Wang, N., & Gong, C. (2025). Advancements in CRISPR/Cas systems for disease treatment. Acta Pharmaceutica Sinica B, 15(6), 2818. https://doi.org/10.1016/j.apsb.2025.05.007
Xu, Y., & Li, Z. (2020). CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Computational and Structural Biotechnology Journal, 18, 2401. https://doi.org/10.1016/j.csbj.2020.08.031
Yoshimi, K., Takeshita, K., Kodera, N., Shibumura, S., Yamauchi, Y., Omatsu, M., Umeda, K., Kunihiro, Y., Yamamoto, M., & Mashimo, T. (2022). Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-32618-0
Zhang, F. (2019). Development of CRISPR-Cas systems for genome editing and beyond. Quarterly Reviews of Biophysics, 52. https://doi.org/10.1017/s0033583519000052
Zhang, M., Li, H., & Jin, Y. (2024). Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Frontiers in Genetics, 15. https://doi.org/10.3389/fgene.2024.1364742
Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021). Review of applications of CRISPR-Cas9 gene-editing technology in cancer research. Biological Procedures Online, 23(1). https://doi.org/10.1186/s12575-021-00151-x
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024). Precise genome-editing in human diseases: Mechanisms, strategies and applications. Signal Transduction and Targeted Therapy, 9(1), 47. https://doi.org/10.1038/s41392-024-01750-2
Zhou, L., & Yao, S. (2023). Recent advances in therapeutic CRISPR-Cas9 genome editing: Mechanisms and applications. Molecular Biomedicine, 4(1). https://doi.org/10.1186/s43556-023-00115-5
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Hanna Porwolik, Agata Porwolik, Radosław Szydłowski, Patryk Cyran, Magdalena Bodera, Anna Kaźmierska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
